Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry (Q35584152)

9 August 2017

1 reference

title

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry (English)

1 reference

9 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14618296

2 April 2024

1

Ulrich M Zanger

1 reference

9 August 2017

Sebastian Raimundo

2

1 reference

9 August 2017

Michel Eichelbaum

series ordinal

3

1 reference

9 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14618296

2 April 2024

publication date

15 November 2003

1 reference

full work available at URL

9 August 2017

http://link.springer.com/content/pdf/10.1007/s00210-003-0832-2.pdf

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1007/S00210-003-0832-2

http://link.springer.com/article/10.1007/s00210-003-0832-2/fulltext.html

2 April 2024

1 reference

https://api.crossref.org/works/10.1007/S00210-003-0832-2

http://link.springer.com/content/pdf/10.1007/s00210-003-0832-2

2 April 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1007/S00210-003-0832-2

Naunyn-Schmiedeberg's Archives of Pharmacology

2 April 2024

published in

1 reference

9 August 2017

369

1 reference

9 August 2017

1

1 reference

9 August 2017

23-37

1 reference

https://scigraph.springernature.com/pub.10.1007/s00210-003-0832-2

9 August 2017

0 references

cites work

Medical implications of HGP's sequence of chromosome 22

1 reference

12 December 2020

Potent Inhibition of Cytochrome P450IID6 (Debrisoquin 4-Hydroxylase) by Flecainide In Vitro and In Vivo

1 reference

12 December 2020

Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene

1 reference

12 December 2020

Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease.

1 reference

12 December 2020

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1 reference

12 December 2020

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

1 reference

12 December 2020

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

1 reference

12 December 2020

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

1 reference

12 December 2020

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment

1 reference

12 December 2020

Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

1 reference

12 December 2020

CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers

1 reference

12 December 2020

Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

1 reference

12 December 2020

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

1 reference

12 December 2020

CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression

1 reference

12 December 2020

Use of probe drugs as predictors of drug metabolism in humans

1 reference

12 December 2020

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis

1 reference

12 December 2020

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes

1 reference

12 December 2020

Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

1 reference

12 December 2020

Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group

1 reference

12 December 2020

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

1 reference

12 December 2020

Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children

1 reference

12 December 2020

Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

1 reference

12 December 2020

MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

1 reference

12 December 2020

1 reference

12 December 2020

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles

1 reference

12 December 2020

Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes

1 reference

12 December 2020

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

1 reference

12 December 2020

Nomenclature for human CYP2D6 alleles.

1 reference

12 December 2020

Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.

1 reference

12 December 2020

The genetic controlof bufuralol metabolisminman

1 reference

12 December 2020

PCR-based genotyping for duplicated and deleted CYP2D6 genes

1 reference

12 December 2020

A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction

1 reference

12 December 2020

Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6.

1 reference

12 December 2020

Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects

1 reference

12 December 2020

Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians

1 reference

12 December 2020

Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines

1 reference

12 December 2020

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

1 reference

12 December 2020

Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells

1 reference

12 December 2020

10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes

1 reference

12 December 2020

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

1 reference

12 December 2020

Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population

1 reference

12 December 2020

High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5' nuclease chain reaction assay

1 reference

12 December 2020

An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis

1 reference

12 December 2020

Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol

1 reference

12 December 2020

Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer

1 reference

12 December 2020

Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6

1 reference

12 December 2020

Tryptamine: a possible endogenous substrate for CYP2D6.

1 reference

12 December 2020

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

1 reference

12 December 2020

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

12 December 2020

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man

1 reference

12 December 2020

Clinical significance of genetic influences on cardiovascular drug metabolism

1 reference

12 December 2020

Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms

1 reference

12 December 2020

Alternative splicing of CYP2D mRNA in human breast tissue

1 reference

12 December 2020

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

1 reference

12 December 2020

(+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

The influence of enzyme induction on polymorphic sparteine oxidation

1 reference

12 December 2020

Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.

1 reference

12 December 2020

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

1 reference

12 December 2020

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

1 reference

12 December 2020

A predictive model for substrates of cytochrome P450-debrisoquine (2D6)

1 reference

12 December 2020

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

1 reference

12 December 2020

Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study

1 reference

12 December 2020

Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling

1 reference

12 December 2020

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

12 December 2020

Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data

1 reference

12 December 2020

Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population

1 reference

12 December 2020

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

1 reference

12 December 2020

Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver

1 reference

12 December 2020

The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site

1 reference

12 December 2020

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

1 reference

12 December 2020

Evidence for CYP2D6 expression in human lung

1 reference

12 December 2020

Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients

1 reference

12 December 2020

Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics.

1 reference

12 December 2020

CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver

1 reference

12 December 2020

Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.

1 reference

12 December 2020

Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype

1 reference

12 December 2020

Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity

1 reference

12 December 2020

Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis

1 reference

12 December 2020

Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

1 reference

12 December 2020

The DNA sequence of human chromosome 22

1 reference

12 December 2020

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

12 December 2020

Oxidation phenotype--a major determinant of metoprolol metabolism and response

1 reference

12 December 2020

Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction

1 reference

12 December 2020

Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine

1 reference

12 December 2020

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver

1 reference

12 December 2020

49 Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6

1 reference

12 December 2020

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

1 reference

12 December 2020

Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

1 reference

12 December 2020

Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man

1 reference

12 December 2020

Pharmacogenetics and adverse drug reactions

1 reference

12 December 2020

Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans

1 reference

12 December 2020

CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.

1 reference

12 December 2020

Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.

1 reference

12 December 2020

Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype

1 reference

12 December 2020

Crystal structure of human cytochrome P450 2C9 with bound warfarin

1 reference

12 December 2020

Inhibitory effects of neuroleptics on debrisoquine oxidation in man

1 reference

12 December 2020

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis

1 reference

12 December 2020

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1 reference

12 December 2020

Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices

1 reference

12 December 2020

Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers

1 reference

12 December 2020

Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction

1 reference

12 December 2020

Gene expression in distinct regions of the heart

1 reference

12 December 2020

Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues

1 reference

12 December 2020

Identification of the primary gene defect at the cytochrome P450 CYP2D locus.

1 reference

12 December 2020

Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles.

1 reference

12 December 2020

Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain

1 reference

12 December 2020

Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.

1 reference

12 December 2020

Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype

1 reference

12 December 2020

The relationship between paroxetine and the sparteine oxidation polymorphism

1 reference

12 December 2020

Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization.

1 reference

12 December 2020

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

12 December 2020

Molecular mechanisms of genetic polymorphisms of drug metabolism

1 reference

12 December 2020

Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia

1 reference

12 December 2020

A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.

1 reference

12 December 2020

Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.

1 reference

12 December 2020

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

1 reference

12 December 2020

Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

1 reference

12 December 2020

CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.

1 reference

12 December 2020

Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.

1 reference

12 December 2020

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry

1 reference

12 December 2020

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

1 reference

12 December 2020

Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?

1 reference

12 December 2020

Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s

1 reference

12 December 2020

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs

1 reference

12 December 2020

Lung Cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association

1 reference

12 December 2020

In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone

1 reference

12 December 2020

Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase

1 reference

12 December 2020

The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene

1 reference

12 December 2020

Dopamine formation from tyramine by CYP2D6.

1 reference

12 December 2020

Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene

1 reference

12 December 2020

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

1 reference

12 December 2020

Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes

1 reference

12 December 2020

The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.

1 reference

12 December 2020

Pharmacogenetics of the major polymorphic metabolizing enzymes.

1 reference

12 December 2020

Cytochrome P -450 activities in human and rat brain microsomes

1 reference

12 December 2020

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism

1 reference

12 December 2020

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

12 December 2020

Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6

1 reference

12 December 2020

Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships

1 reference

12 December 2020

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

12 December 2020

Human CYP allele database: submission criteria procedures and objectives.

1 reference

12 December 2020

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment

1 reference

12 December 2020

Identifiers

DOI

1 reference

9 August 2017

1 reference